ERIC
CORT icon

Eagle Rock Investment Company’s Corcept Therapeutics CORT Stock Holding History

Eagle Rock Investment Company’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Buy
+4,750
New +$287K 0.05% 125
2025
Q4 		– Sell
-4,750
Closed -$395K – 166
2025
Q3 		$395K Buy
4,750
+750
+19% +$54.3K 0.06% 129
2025
Q2 		$294K Buy
4,000
+1,000
+33% +$72.5K 0.05% 138
2025
Q1 		$343K Buy
+3,000
New +$183K 0.06% 132

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Eagle Rock Investment Company's CORT Position: Q2 2026 in Review

Eagle Rock Investment Company opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4,750 shares worth $413K. The stake represents 0.05% of the portfolio and ranks #125 among its holdings. This is a return to the name: Eagle Rock Investment Company previously reported a position in CORT as recently as Q3 2025.

Eagle Rock Investment Company first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. 240 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Eagle Rock Investment Company held 4,750 shares of Corcept Therapeutics worth $413K as of Q2 2026.
  • Corcept Therapeutics was a new Eagle Rock Investment Company position in Q2 2026.
  • Corcept Therapeutics made up 0.05% of Eagle Rock Investment Company's portfolio in Q2 2026, its #125 holding.
  • Eagle Rock Investment Company first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 240 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Eagle Rock Investment Company's 13F filing for Q2 2026, filed 9 Jul 2026.